For example, serum FGF2 levels were higher in patients with ovarian cancer than in people with benign ovarian tumors or normal ovaries (21); the growth of ovarian cancer was regulated by FGF8 (22); overexpression of FGF18 was an independent predictive marker for poor outcomes in patients with high-grade serous ovarian cancer (23). This evidence concerns the gene FGF18 and ovarian cancer.